Abstract
Duration: 20 minutes
This webinar features data demonstrating the utility of RBM’s new product, the SARS-CoV-2 Spike Protein TruCulture tube.
Anne Hwang, PhD
Scientist III
RBM, Inc.
Shen-An (Anne) Hwang joined Myriad RBM (now Rules-Based Medicine, a Q2 Solutions Company) in January 2018 to support the TruCulture® platform technology and contribute to advancements in areas of production application and clinical diagnostic platform development. Prior to joining RBM, she was an assistant professor at the University of Texas McGovern Medical School at Houston specializing in immunopathology and vaccine/adjuvant development. She obtained her PhD (2006) in immunology from the University of Texas Health Science Center at Houston.
